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MitochondriaPC) affords cardioprotection against ischemia–reperfusion (IR) injury, and while
the molecular mechanisms of IPC are debated, the mitochondrial ATP-sensitive K+ channel (mKATP) has
emerged as a candidate effector for several IPC signaling pathways. The molecular identity of this channel is
unknown, but signiﬁcant pharmacologic overlap exists between mKATP and mitochondrial respiratory
complex II (succinate dehydrogenase). In this investigation, we utilized isolated cardiac mitochondria,
Langendorff perfused hearts, and a variety of biochemical methods, to make the following observations:
(i) The competitive complex II inhibitor malonate is formed in mitochondria under conditions resembling
IPC. (ii) IPC leads to a reversible inhibition of complex II that has likely been missed in previous investigations
due to the use of saturating concentrations of succinate. (iii) Malonate opens mKATP channels even when
mitochondria are respiring on complex I-linked substrates, suggesting an effect of this inhibitor on the mKATP
channel independent of complex II inhibition. Together, these observations suggest that complex II inhibition
by endogenously formed malonate may represent an important activation pathway for mKATP channels
during IPC.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
The acute pathology of cardiac ischemia–reperfusion (IR) injury is
largely mediated through a series of key events at the mitochondrial
level, including mitochondrial Ca2+ overload and the overproduction
of reactive oxygen species (ROS) [11,62,68], which trigger opening of
the mitochondrial permeability transition (PT) pore at reperfusion
[29,41], leading to cytochrome c release and cell death. In contrast,
despite being a site of damage, mitochondria are also implicated in
the endogenous cardioprotective mechanism of ischemic precondi-
tioning (IPC), in which short non-lethal periods of IR protect the
heart from subsequent prolonged IR injury [48]. Preservation of
mitochondrial function is critical to post-ischemic functional recovery
[1,36,43,57,62,67], and the cardioprotective effect of IPC can be
mimicked by various pharmacological agents which act at the
mitochondrial level [6,14,35,56,60,74]. Most notable among these
agents are activators of mitochondrial ATP-sensitive potassium
channels (mKATP) [16,23] and reversible inhibitors of the respiratory
chain complexes [13,14,49,58,61]. To date, an overlap in the mechan-
ism of protection afforded by thesemitochondrial targets has not been
fully elucidated.1 585 273 2652.
P.S. Brookes).
ll rights reserved.Extensive pharmacological evidence implicates the mKATP channel
in IPC [4,30,47]. Diazoxide (DZX), a pharmacological agonist of mKATP
mimics IPC [28,45], while mKATP antagonists prevent both IPC and
DZX-mediated cardioprotection [5,37,65]. Initially, the pharmacologi-
cal effects of KATP modulators were attributed to classic surface KATP
channels, causing a shortening of action potentials and thereby
depressing contractility [51]. However, the protective effect of KATP
modulators remains in non-contracting cardiomyocytes [44,45]. The
detection of a KATP channel in the inner mitochondrial membrane
[8,38] correlated the pharmacological evidence, but despite extensive
investigation the mechanisms of endogenous upstream regulation of
mKATP activity during IPC remain elusive. The mechanism of
protection downstream of mKATP opening also remains unclear [16],
but may involve mild uncoupling [17,42] resulting in the inhibition of
Ca2+ overload and ROS generation [42]. Alternatively, mKATP-mediated
K+ inﬂux may result in water inﬂux, causing mild matrix swelling [21]
that may improve coupling of Ox-Phos or interfere with PT pore
assembly [16,17].
The pharmacological evidence implicating mKATP in IPC also
alludes to a role for complex II (succinate dehydrogenase, SDH) in
IPC [3]. Complex II is a trans-membrane protein of the mitochondrial
respiratory chain, and also an enzyme of the TCA cycle, transferring
electrons from succinate oxidation onto ubiquinone. Interestingly, IPC
is known to trigger endogenous mechanisms that reversibly inhibit
Fig. 1. Effects of IPC and ATP on mitochondrial complex II activity. (A) Hearts were
subjected to Langendorff perfusion protocols as detailed in Materials and methods and
mitochondria were isolated from the perfused hearts. Freeze–thawed mitochondria were
subjected to a complex II activity assay which was initiated by the addition of 20 mM
succinate. Control activity was 87±3.6 nmol/min/unit citrate synthase. (B) Intact, isolated
mitochondria were subjected to a complex II activity assay, in the absence or presence of
1 mM ATP. Control activity was 82±12.2 nmol/min/unit citrate synthase. Data are
normalized to percent of control. All data are means±SEM, N≥3. ⁎pb0.05 vs. control.
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mKATP agonist DZX [15] inhibits complex II [20,64], while complex II
inhibitors such as 3-NP [53] and HNO [25,55,66] have been shown to
mimic IPC and protect both the heart [53] and brain against IR injury
[61]. Genetic overlap between complex II subunit C and the sulfonylurea
receptor of KATP channels has also been reported [73]. Theseﬁndings led
to the hypothesis that respiratory chain inhibition rather than mKATP
channel activity may underlie IPC-mediated protection, and generated
some doubt regarding the existence of mKATP [3,18]. The lack of a
molecular identity for mKATP compounded these doubts, and led to
proposals that the channel may be composed of preexisting mitochon-
drial proteins, including complex II, mitochondrial ATP-binding cassette
protein-1, adenine nucleotide translocator, ATP synthase, and the
phosphate carrier [3]. In parallel, complex II inhibitors such asmalonate
and 3-NP also trigger K+ transport, suggesting that complex II may be a
component of, or important regulator of, the mKATP channel [3].
Another important characteristic of themKATP channel appears to be
its complex interactionswithmitochondrial ROS generation. It has been
reported that ROS reside either upstream [22] or downstream [2] of
mKATP within the signaling cascade of IPC. However, the molecular
mechanisms by which ROSmay regulate channel activity are unclear. In
this regard, it has been recently shown that several metabolic α-keto
acids of the TCA cycle can react with H2O2 to undergo non-enzymatic
decarboxylation [24], to generate molecules capable of regulating the
respiratorychain.Among themost biologically relevant of such reactions
are the conversions of pyruvate→acetate, α-ketoglutarate→succinate,
and oxaloacetate (OAA)→malonate [24]. Notably, both OAA and
malonate are competitive inhibitors of complex II, but with very dif-
ferent inhibitory properties. Thus, we hypothesized that OAA may be
converted to malonate during IPC, leading to reversible complex II
inhibition. In addition we hypothesized that malonate inhibition of
complex II would regulate mKATP channel activity. In this investigation,
isolated cardiacmitochondriawere studied to elucidate apotential novel
mechanism of mKATP channel regulation in the context of IPC.
2. Materials and methods
Male Sprague–Dawley rats of 200–225 g body mass were purchased from Harlan
(Indianapolis, IN) and housed on a 12 h light/dark cycle with food and water available
ad libitum. All procedures were performed in accordancewith the US National Institutes
of Health “Guide for the care and use of laboratory animals”. Unless otherwise stated, all
chemicals were of the highest grade obtainable, from Sigma (St. Louis MO).
Isolated rat hearts were retrograde perfused using the Langendorff method, in
constant-ﬂowmode (12ml/min), as previously described [10,70]. Heartswere subjected
to one of the following global ischemia or IPC protocols: 1) control: 1 h normoxic
perfusion, 2) ischemia: 25 min normoxic perfusion plus 25 min ischemia, 3) IPC alone:
3 cycles of 5min ischemia followed by 5min reperfusion, and 4) IPC+ ischemia: IPC as in
protocol 3, followed by 25 min ischemia.
Mitochondria were isolated either from fresh rat hearts or following the above
protocols by differential centrifugation in sucrose-based buffer as previously described
[13,50,70], with slight modiﬁcations to ensure rapid isolation (b45 min total), to preserve
mKATPactivitywhich deteriorated rapidly, despite storingmitochondria on ice (see below).
Proteinwas determined using the Folin-phenol method [46]. Sub-mitochondrial particles
(SMPs) were prepared from frozen isolated mitochondria by diluting to 15 mg/ml in SMP
buffer (20mMMOPS, pH 7.2, 4 °C), followed by 7 sonication cycles of 30 s on/30 s off. The
suspensionwas centrifugedat16,000 ×g for 10min, thepelletdiscarded, the centrifugation
repeated, and the resulting supernatant then centrifuged at 100,000 ×g for 45 min. The
SMP pellet was resuspended in 0.5 ml buffer [13].
Complex II enzymatic activity was determined spectrophotometrically as the rate
of succinate-driven, co-enzyme Q2-linked reduction of dichlorophenolindophenol
(DCPIP) [70]. Mitochondria or SMPs were incubated in phosphate buffer (pH 7.4)
containing 40 µMDCPIP,1 mMKCN,10 µM rotenone, and 50 µM co-enzyme Q2. The rate
of reduction of DCPIP to DCPIPH2 was followed at 600 nM (ε=21,000 M−1). Varying
amounts of succinate and inhibitors were used, as detailed in the ﬁgures and legends. At
the end of each run thenoyltriﬂuoroacetone (1 mM) was added and the residual TTFA-
insensitive rate was subtracted.
HPLC analysis of α-keto acids and TCA-cycle intermediates was performed
essentially as described [24]. Heart mitochondria (5 mg/ml) were set to respire on
5 mM malate and 10 mM succinate, in 125 mM KCl, 10 mM HEPES, 1.5 mM phosphate,
pH 7.4, 37 °C, with continuous stirring in open cuvets for 1 h. Additions of H2O2 or
glutathione (GSH) weremade during the incubations, thenmitochondriawere added to
HClO4 (3% ﬁnal) and pelleted by centrifugation. Supernatants were analyzed using two
Aminex HPX-87H columns (300×7.8 mm; Bio-Rad) in series, at a ﬂow rate of 0.7 ml/minwith 10 mM H2SO4 mobile phase, at 35 °C, with detection at 210 nm. Calibration curves
were constructed using standard solutions of authentic acids, and internal standards
were spiked into all samples.
mKATP channel activity was measured by the commonly used swelling/light-scatter
assay [7,26,27,33,42,59], at 520 nm using a Beckman DU800 spectrophotometer. There
has been much debate regarding the existence of mKATP, and several laboratories have
used a light-scatter/swelling assay to characterize this channel [7,22,26,42,59].
However, other groups have not been able to repeat these experiments [18]. During
the course of initiating these studies, we found that a critical factor determining the
ability to measure mKATP channel activity is freshness of mitochondria. Typical
mitochondrial isolation protocols consist of either 3 high-speed centrifugation steps (7–
10,000 ×g), or gradients of Percoll™, all followed by ~1 h incubation of the ﬁnal
mitochondrial pellet on ice, during which time the protein assay is performed. We
found that such mitochondria were devoid of mKATP channel activity in the swelling
assay. Modiﬁcations to our standard method determined via empirical practice, led to
our ability to measure this channel. Firstly, we omitted one high-speed spin from the
mitochondrial isolation method, thereby reducing the total time by ~15 min, and we
compensated for any effect of this on mitochondrial purity by discarding more material
at each step and sacriﬁcing mitochondrial yield. Secondly, we performed a very fast
protein assay based on optical density, and began to measure mKATP channel activity as
soon as themitochondriawere ready, and then returned at a later time point to perform
the standard quantitative protein assay [46]. Despite these modiﬁcations, we routinely
found that mKATP channel activity deteriorated within 1.5 h of beginning experiments.
Mitochondria (0.25 mg/ml) were rapidly added to a stirred cuvette containing
mKATP buffer (100 mM KCl, 10 mMHEPES, 2 mM succinate, 2 mMMgCl2, 2 mM KH2PO4,
1 µg/ml oligomycin, pH 7.2 at 37 °C). In some experiments, as indicated by ﬁgure
legends, K+ in the buffer was replaced with Na+, or complex I-linked substrates (2 mM
glutamate+2 mM malate) were used instead of succinate.
3. Results
While it has previously been shown that complex II-linked respira-
tion is somewhat decreased following IPC [58], it was not known if this
was due to a de-facto inhibition of complex II itself, or possibly due to
effects on substrate transport intomitochondria. In Fig.1A,mitochondria
were rapidly isolated from hearts that underwent control perfusion or
IPC alone protocol (3×5 min ischemia interspersed with 5 min
reperfusion), freeze–thawed, and then subjected to complex II activity
assays. The data show that IPC mitochondria exhibited a small (12%) but
signiﬁcant decrease in complex II activity, which thus cannot be
attributed to inhibition of substrate transport into mitochondria. In
Fig. 1B, control mitochondria were incubated in the standard complex II
activity assay (seeMaterials andmethods), in the absence or presence of
1 mM ATP. This concentration of ATP, which is typically used to inhibit
mKATP channel activity, caused a stimulation of complex II activity. This
result is consistent with previous reports that ATP can allosterically
activate complex II [32], although it was felt to be important to recon-
stitute this ﬁnding in the currentmodel system (rat heartmitochondria).
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known, but since IPC leads to the generation of ROS such as H2O2
[71,72] and it is known that H2O2 can non-enzymatically decarbox-
ylatemetabolicα-keto acids [24], we hypothesized that such reactions
may occur in IPC, thereby generating molecules capable of regulating
complex II activity. However, initial experiments investigating meta-
bolic acid proﬁles in mitochondria isolated from IPC hearts were not
successful (due to possible redistribution of metabolite pools during
the isolation process). Similarly, whole-heart extracts were not
compatible with the HPLC method (too many additional species
absorbing in the UV range). Thus, a model system was established, in
which isolated mitochondria were incubated with substrates, and
various concentrations of oxidants and antioxidants were added, to
mimic IPC. The data in Fig. 2A show that the HPLC method developed
is capable of detecting malonate in the mitochondrial matrix. While
the formation of malonate from the oxidative decarboxylation of OAA
has previously been shown only in free solution, and hypothesized to
occur inside mitochondria [24], these data show for the ﬁrst time that
this reaction actually does occur inside mitochondria. While OAA was
not reliably detectable by HPLC (owing to its rapid decomposition to
pyruvate in free solution, unpublished observations), we could clearly
observe that under oxidative conditions (100 or 300 µM H2O2) the
levels of another α-keto acid, α-ketoglutarate, were decreased
(Fig. 2B). Furthermore, addition of 1 mM GSH to the incubations
abrogated the effect of H2O2. In addition, malonate levels (presumably
from the oxidative decarboxylation of OAA) increased in the presence
of H2O2, and this effect was also blocked by GSH. Notably, the baseline
level of malonate (i.e. no H2O2 added) was also decreased by a small
but signiﬁcant amount in the presence of GSH, suggesting that
malonate may be generated under normal mitochondrial functionalFig. 2. H2O2-mediated generation of malonate in mitochondria. (A) The HPLC elution
proﬁles (A210) of TCA-cycle intermediates in mitochondria from 15 to 18 min in the
presence of 0 mM H2O2 (ctrl.), 100 µM H2O2, 300 µM H2O2, or 1 mM GSH. Peaks
correspond to the following: α-KG, 14.8 min; malate/pyruvate, 16.1 min; and malonate,
17.3 min. (B and C) Quantiﬁcation of the elution proﬁles using a standard curve and an
internal standard for α-KG and malonate. All data are means±SEM, N≥4. ⁎pb0.05 vs.
ctrl. †pb0.05 vs. 300 µM H2O2.
Fig. 3. Effects of OAA, malonate, H2O2, and IPC, on mitochondrial complex II activity and
succinate kinetics. (A) Titration of complex II activity was determined using SMPs. The
initial rate (100%) was set by adding 2.5 mM succinate (apparent KM, determined
elsewhere). Gray squares, OAA; open triangles, OAA+H2O2; black squares, malonate;
and open circles, H2O2. Inset shows values of IC50 for each inhibitor. (B) The inhibition
and recovery of complex II activity. Initial rate (100%) of complex II activity in SMPs, was
inhibited to ~50% with either malonate (black squares) or OAA (gray squares). Activity
was then recovered by titrating back in succinate, to remove the competitive inhibitors.
(C) Oxygen consumption (nmol O2/min/mg protein) utilizing succinate, measured using
a Clark-type oxygen electrode, was determined in mitochondria isolated from
Langendorff perfused hearts subjected to either ischemia alone (open squares), or
ischemiawith prior IPC (ﬁlled squares). Upper inset shows values of Vmax (nmol O2/min/
mg) and KM (mM succinate). Lower inset is the concentration of succinate from 0 to
8 mM. All data are means±SEM; N≥4.conditions, possibly driven by endogenously generated H2O2 from the
respiratory chain.
Although both OAA and malonate are inhibitors of complex II
[19,31,40], they exhibit very different kinetic effects on the enzyme,
and thus it is possible that the ROS-driven inter-conversion of OAA to
malonate may change the proﬁle of complex II regulation during IPC.
Furthermore, it is known that malonate and OAA may compete for
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inhibitor) may be able to displace OAA (the stronger) [40]. Thus, it was
decided to investigate the interactions of various ROS and TCA-cycle
acids with complex II activity. SMPs were used as a model system
since they are free of matrix enzymes and transport functions, and we
have found that dose responses to OAA were signiﬁcantly affected by
uptake of the inhibitor across the mitochondrial membrane (data not
shown). In Fig. 3A, SMPs were incubated with 2.5 mM succinate to
drive complex II, followed by addition of either, malonate, OAA, H2O2,
or OAA plus H2O2. The data show that H2O2 alone only caused mild
inhibition of complex II activity, and was without any signiﬁcant effect
at concentrations below 35 µM. By contrast, OAA-inhibited complex II
with an IC50 of ~18 µM. Malonate was not as potent as OAA, inhibiting
complex II with an IC50 of ~40 µM.Most notably though, is the effect of
adding OAA and H2O2 together. Far from the expected result (an
additive inhibitory effect), this combination of reagents led to a
weaker level of inhibition than seen for OAA alone. In-fact, the proﬁle
of complex II inhibition seen in the presence of OAA plus H2O2
resembles that of malonate more than it does that of OAA alone. These
data suggest that H2O2 is driving the oxidative decarboxylation of OAA
to malonate, resulting in a malonate-like inhibition proﬁle.Fig. 4. Recapitulation of the mKATP channel swelling/light-scatter assay in isolated rat heart m
Representative swelling traces ofmitochondria (~0.25mg/ml) inK+media suppliedwith2mMs
(B) Magnitude of swelling, relative to control, as determined by a decrease in absorbance after 0
0.2min resulted in a decrease inA520 of 0.0210±0.001ODunits in K+media and 0.0200±0.002O
SEM ⁎pb0.05 vs. control, ⁎⁎pb0.05 vs. ATP, ⁎⁎⁎pb0.05 vs. ATP+DZX; N≥4.In the next series of experiments, SMPs were incubated with
2.5 mM succinate, followed by titrating in OAA or malonate to
concentrations that elicited 50% inhibition of complex II activity (i.e.
their IC50 values). Succinate was then titrated back in, up to 8 mM, and
the reversal of complex II inhibition was observed. Consistent with
OAA being a more tight-binding inhibitor than malonate, the OAA-
inhibited complex II did not recover as fully as malonate-inhibited
complex II (Fig. 3B). The apparent recovery of malonate-inhibited
complex II activity to a value greater than 100% is due to the use of
higher concentrations of succinate in recovery titrations than present
during initial inhibition titrations.
Following ischemia, the recovery of respiratory chain activity upon
reperfusion is essential to allow Ox-Phos to generate ATP for
contraction of the heart. Thus, it could be hypothesized that the
mode of complex II inhibition (i.e. OAA- or malonate-mediated) could
impact on the recovery of complex II activity during reperfusion. To
test this hypothesis, mitochondriawere isolated from hearts subjected
to ischemia, or ischemia with prior IPC, and their succinate-titration
proﬁles were determined. The data in Fig. 3C show that at low
concentrations of succinate (b1 mM), mitochondria from the hearts
subjected to IPC exhibit a faster respiration rate. Put differently, theitochondria. (A) Osmotic swelling assay for determination of the mKATP channel activity.
uccinate.Where indicated,1mMATP,10 µMDZX, or 300 µM5HDwaspresent in themedia.
.2 min incubation in K+ media (ﬁlled bars) or Na+media (open bars). Control swelling after
D units inNa+media. Experimental conditions are listed below the x-axis. Data aremeans±
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(decreased) in the IPC hearts. Complex II is inhibited during ischemia by
OAA, which accumulates due to stoppage of the TCA cycle at citrate
synthase (no entry of substrates at acetyl-CoA). Thus, the left-shifted
succinate-titration curve in the IPC hearts suggests that the mode of
inhibitionmay be shifted to amoremalonate-like proﬁle. It is postulated
that this malonate generation could be driven by H2O2 generated during
IPC. Notably, in contrast with previous ﬁndings [58], higher concentra-
tions of succinate elicited almost identical respiration rates in mitochon-
dria from ischemia vs. IPC+ischemia hearts. It is postulated that
differences in succinate titration and delivery may be responsible for
these contrasting results. Indeed, most mitochondrial studies use bolus
high concentrations of substrates (e.g. in oxygen electrode incubations)
and it is suggested that subtle variations in complexactivities suchas seen
here may have been overlooked. These data highlight the importance of
substrate availability in determiningmitochondrial function, and suggest
that adding saturating concentrations of substrates to isolatedmitochon-
drial incubations may mask a variety of critical information.
As discussed in the introduction, a substantial pharmacologic
overlap exists between the mKATP channel and complex II, and thus
our next series of experiments sought to characterize the possible link
between the endogenous complex II inhibitormalonate and themKATP
channel, in IPC.Fig. 5. Effects of malonate on mKATP channel activity. (A) Representative swelling traces of m
1 mM ATP, 100 µM malonate, or 300 µM 5HD was present in the media. (B) Magnitude of
incubation in K+ media supplied with 2 mM succinate (ﬁlled bars) or 2 mM glutamate+2 m
decrease in A520 of 0.0153±0.001 OD units. Experimental conditions are listed below the x-
N≥4.The data in Fig. 4A demonstrate the successful reconstitution of the
mKATP channel activity swelling assay in this laboratory. Mitochon-
drial swelling in K+ based buffer [22] was inhibited by ATP, and this
inhibition was reversed by DZX (Fig. 4B, ﬁlled bars). Notably, only
10 µM DZX was required; a concentration that does not inhibit
complex II [20,64]. The effect of DZX was reversed by the mKATP
channel inhibitor 5-hydroxydecanoate (5HD), and furthermore the
repetition of these incubations in a medium in which all K+ was
replaced with Na+, resulted in loss of all pharmacologic effects (Fig. 4B,
open bars). The non-speciﬁc KATP channel blocker glyburide gave the
same effects as 5HD. Also, it is known that themKATP channel is redox-
sensitive [22], and its opening can be inhibited by antioxidants such as
MPG. The mKATP channel activity indicated herein was also inhibited
by MPG (Fig. 4B). While the speciﬁcity of some individual mKATP
channel modulators (e.g. DZX, 5HD) has recently been questioned
[34], we believe that this complex combination of pharmacologic
agents (ATP/DZX/Glyburide/5HD/MPG) is a reliable assay of mKATP
channel function. Cromakalim and pinacidil also modulated mKATP
channel activity in this assay (data not shown).
Having established a reliable mKATP channel assay, we next sought
to examine the effects of malonate on mKATP channel activity. The
results in Fig. 5A and B (ﬁlled bars) show that malonate (25–100 µM)
was able to mimic and surpass the effect of DZX, leading to activationitochondria (~0.25 mg/ml) in K+ media supplied with 2 mM succinate. Where indicated,
swelling, relative to control, as determined by a decrease in absorbance after 0.2 min
M malate (open bars). Control swelling supplied with glutamate+malate resulted in a
axis. ⁎pb0.05 vs. control, ⁎⁎pb0.05 vs. ATP, ⁎⁎⁎pb0.05 vs. ATP+DZX or ATP+malonate;
887A.P. Wojtovich, P.S. Brookes / Biochimica et Biophysica Acta 1777 (2008) 882–889of swelling which was inhibited by 5HD. The pharmacological effects
of malonate-induced mKATP channel activity were both inhibited by
glyburide and MPG, and were lost in a Na+-based media (data not
shown).
Since malonate is a competitive inhibitor of complex II, the
concentrations of succinate, malonate and complex II itself, determine
the degree of inhibition. Utilizing the same conditions as in the mKATP
swelling assay, the concentrations of malonate which activated mKATP
activity, exhibited little or no effect on complex II activity (100 µM
malonate ~20% inhibition, data not shown). Note that the inhibition
proﬁle for malonate seen in Fig. 3A is different, as those data were
obtained in SMPs.
Perhaps themost notable property ofmalonate stimulation ofmKATP
activity was that swelling also occurred in mitochondria respiring on
complex I-linked substrates (glutamate plus malate, Fig. 5B, open bars).
These data indicate thatmalonate may have an effect onmKATP channel
activity that is independent of effects complex II activity. This is in
agreement with the mismatch in dose responses to malonate, of mKATP
channel opening vs. complex II inhibiton.
4. Discussion
In the current study, we sought to investigate in more detail the
complex inter-relationships between complex II, the mKATP channel,
and ROS, all within the context of IPC. Both complex II inhibitors
[53,61] and mKATP agonists [4,30,47] are protective against IR injury,
and the pharmacological overlap between complex II and the mKATP
channel implicates complex II as a component or regulator of the
channel. For example, the mKATP agonist DZX [15] inhibits complex II
[20,64] and the administration of the complex II inhibitor malonate
can mimic DZX protection and decrease ROS [54]. Furthermore,
reconstitution experiments with complex II, along with at least four
other mitochondrial proteins, reproduced the K+ transporting cap-
abilities of mKATP [3]. These investigations suggest that the inhibition
of complex II is a potential modulator of mKATP activity. Additionally,
another link between complex II modulation and mKATP activity can
be demonstrated by the use of ﬂavoprotein ﬂuorescence as a measure
of channel activity, albeit under very speciﬁc conditions [45,63]. The
main source of ﬂavoprotein ﬂuorescence in cells is attributed to the
FAD associated with TCA-cycle dehydrogenases, such as complex II
[32]. Overall, the emerging consensus from this and other studies is
that complex II and mKATP are inversely related — i.e. inhibition of
complex II is correlated with channel opening, while activation of
complex II is correlated with channel closing. The fact that we herein
observed effects of mKATP channel regulators on complex II, in an
experimental system without mKATP channel activity (SMPs and
frozen mitochondria), suggests that complex II lies upstream of the
channel, not vice-versa.
In this study, the detection of endogenous complex II inhibitors in
conditions thatmimic IPC (Fig. 2) supports the concept of an overlap in
cardioprotection afforded by complex II inhibition andmKATP opening.
The IPC-mediated inhibition of complex II activity is consistent with
the results of Pasdois et al. [58], who additionally showed that the IPC-
mediated inhibition is reversed post-reperfusion. Investigations to
date have supported the hypothesis that reversible inhibition of the
respiratory chain is protective in IR injury [12,14] and this inhibition
can be mediated by IPC [13,49,53,58,61]; however, the endogenous
generation of complex II inhibitors in IPC has been overlooked. The
cardioprotective effects of IPC-mediated complex I inhibition have
been previously demonstrated [13,49], and we hypothesize that this
effect could be complemented by complex II inhibition. Mitochondria
are a source of ROS [11], and oxidative conditions associated with IPC
[71] can non-enzymatically decarboxylate α-keto acids in TCA cycle
[24], resulting in the formation of the complex II inhibitor, malonate
(Fig. 2). Themalonate detected herein originatedwithin themitochon-
drial matrix and not in the external medium, since mitochondriaweresupplemented with only malate and succinate as substrates, and thus
any malonate must have originated from OAA generated by the TCA
cycle. Assuming a typical heart mitochondrial matrix volume of 0.65 µl
per mg protein [50], 20 pmol malonate per mg equates to an intra-
mitochondrial concentration of 30 µM. Thus, while the absolute
amounts of malonate generated in these in-vitro incubations are low,
they may still be of physiological relevance inside the mitochondrial
matrix. The observation that malonate-mediated complex II inhibition
is more easily reversed following reintroduction of succinate (Fig. 3B
and C) is consistent with the importance of inhibition reversal, at
reperfusion.
The effects ofmalonate are not limited to complex II, and a swelling
assaywas used to investigate the effects ofmalonate onmKATP channel
activity. Measuring the matrix volume as a means of monitoring ion
transport in mitochondria is a commonly used technique [9] and has
played a central role in the investigation of the mKATP channel
[7,26,27,33,39,42,52,59,69]. Utilizing this technique, malonate caused
K+-dependent swelling that was prevented by 5HD, glyburide, and
MPG [22]. The uptake of K+ depends on membrane potential, and
despite the use of succinate to energizemitochondria and generate the
membrane potential, the complex II competitive inhibitor malonate
increases swelling. Thus, the effect of malonate cannot be attributed to
its effects on mitochondrial bioenergetic function.
TheK+-dependent swellingwasalso still presentwhenmitochondria
were energized with complex I-linked substrates (glutamate and
malate), thus suggesting that complex II does not need to be active to
modulate themKATP. This data supports the hypothesis that complex II is
involved in the K+-mediated swelling of mitochondria, but the exact
nature of this interaction (i.e. whether complex II is actually part of the
channel, or just regulates the channel activity) is not knownat this stage.
Deﬁnitive conclusions can only be made once the components of the
mKATP are known. It is possible that complex II may indirectly regulate
the channel through changes in themitochondrial redox state or simply
the channel itself may contain a malonate binding site; however, the
observation of K+-dependent swelling with complex I-linked substrates
(Fig. 5A and B) argues for a more direct role of complex II in the
regulation of the mKATP.
The use of DZX to study themKATP arises from the speciﬁcity of this
compound for the mKATP, as opposed to the sarcolemmal KATP. This
speciﬁcity might arise from the interaction with complex II, although
it should be noted that the concentration of DZX used in these
experiments (10 µM) is below that found to inhibit complex II [20,65].
Similarly, the concentrations of malonate which mimicked the ability
of diazoxide to activate mKATP, also do not inhibit complex II activity.
At a time when the identity of the channel remains unknown, a
mechanistic and pharmacological link between complex II modula-
tion and mKATP activation provides a novel means of activating the
mKATP channel. Insight into the temporal relationship between mKATP
channel opening and complex II inhibition is also provided, since both
DZX and IPC-mediated inhibition of complex II persisted in experi-
mental systems in which mKATP channel activity was absent (i.e.
frozen mitochondria and SMPs). Thus, mKATP channel opening does
not appear to be a pre-requisite for complex II inhibition. The reverse
may still be possible however.
In summary, we have herein identiﬁed that the endogenous
complex II inhibitor malonate is generated under conditions mimick-
ing IPC. The ability of malonate to open mKATP channels in a manner
similar to DZX, and regardless of its effects on complex II activity,
suggests the possible therapeutic use of strategies to augment
malonate levels in cardiac mitochondria, to elicit cardioprotection.
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